Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
The importance of event rates for clinical site effects in multicenter trials — John P A Ioannidis (1998) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
The importance of event rates for clinical site effects in multicenter trials
Shared by
John P A Ioannidis
Stanford University
The importance of event rates for clinical site effects in multicenter trials
Article
1998
en
Authors
+3 more
John P A Ioannidis
Stanford University
DD
Dennis O. Dixon
MM
Martin McIntosh
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2002
Reporting the clinical importance of randomized controlled trials.
David Moher
,
Douglas G. Altman
,
Kenneth F. Schulz
Article
2023
Protocol of the CONSORT and SPIRIT Extension for multicenter clinical trials
Xuan Zhang
,
Chongya Dong
,
Nana Wang
,
Chunpong Chan
,
Chung Tai Lau
,
Juan Wang
,
Jiangxia Miao
,
Chen Yao
,
Youping Li
,
Aiping Lyu
,
David Moher
,
Zhaoxiang Bian
Article
2023
The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
Kristian Thorlund
,
Davey M. Smith
,
Christopher Linsell
,
Sir Nicholas White
,
Christopher Butler
,
David R. Boulware
,
Judith S. Currier
,
Ofir Harari
,
Edouard Lhomme
,
Nathalie Strub‐Wourgaft
,
Stacey J. Adam
,
Edward J. Mills
Communications Medicine
Article
2011
Disclosure of Investigators' Recruitment Performance in Multicenter Clinical Trials: A Further Step for Research Transparency
Rafael Dal‐Ré
,
David Moher
,
Christian Gluud
,
Shaun Treweek
,
Jacques Demotes‐Mainard
,
Xavier Carné
Article
2011
Three-year clinical event rates in different age groups after contemporary percutaneous coronary intervention
Neville Kukreja
,
Yoshinobu Onuma
,
Héctor M. García‐García
,
Josephine van Nierop
,
Joost Daemen
,
Ron van Domburg
,
Patrick W. Serruys
EuroIntervention
Discussion(0)
No comments yet. Be the first to comment.